News Release

12/12/2011

Taiho Pharmaceutical Announces Personnel Changes(PDF:215KB)

12/09/2011

Taiho Pharmaceutical to Launch a New Anti-tumor Agent,
ZOLINZA® capsules 100mg, on September 14

22/07/2011

Taiho Pharmaceutical Announces Results of Randomized Phase II Clinical Trial with Novel Antitumor Agent TAS-102 - Positive Results of Overall Survival in Patients with Colorectal Cancer Refractory to Standard Chemotherapy -

21/07/2011

Taiho Pharmaceutical Co., Ltd and Nordic Group BV Enter into a Development and Commercialization Agreement for the recently EMA approved Anti-Cancer Drug Teysuno^™ covering the EU and other Selected European Countries

09/06/2011

MSD K.K. and Taiho Pharmaceutical Co., Ltd. Enter into Distribution Agreement for the Anticancer Compound Vorinostat in Japan(PDF:74KB)

08/06/2011

Presentation of results of GEST clinical study of TS-1 in patients with advanced pancreatic cancer to the American Society of Clinical Oncology

06/06/2011

Presentation to the American Society of Clinical Oncology of results of final analysis of a clinical study in patients with unresectable colorectal cancer (FIRIS study)

13/04/2011

Announcement of License Agreement on a New Antiemetic Combination Agent

25/03/2011

Announcement of Promotion of Managing Director(PDF:38KB)

15/03/2011

TEYSUNO™ (S-1) RECEIVES EUROPEAN MARKETING AUTHORIZATION AS FIRST-LINE THERAPY FOR ADVANCED GASTRIC CANCER

26/01/2011

Taiho Pharmaceutical Announces Results of Gemcitabine and TS-1 Trial (GEST) on Advanced Pancreatic Cancer

20/12/2010

TEYSUNO™ (S-1) RECEIVES CHMP POSITIVE OPINION FOR APPROVAL AS FIRST-LINE THERAPY FOR ADVANCED GASTRIC CANCER

12/10/2010

Regarding the results of a five-year follow-up study in the Adjuvant Chemotherapy Trial of TS-1 for Gastric Cancer (ACTS-GC)

17/09/2010

Antineoplastic ABRAXANE® to be Launched Friday, September 24

23/07/2010

Abraxane® Approved for Marketing in Japan for Breast Cancer

21/04/2010

5-HT₃ Receptor Antagonist, Aloxi® on April 22

20/01/2010

Helsinn Group and Taiho Pharmaceutical Announce Approval of OncologyPalonosetron in Japan,,the World’s Second Largest Pharmaceutical Market

03/08/2009

Taiho to Buy Tsukuba Research Institute from Banyu

21/07/2009

Taiho Pharmaceutical’s Anticancer Agent TS-1 Approved for Market in Singapore

31/03/2009

Taiho Pharmaceutical and PharmaMar of Spain
Sign License Agreement on Antitumor Agent Yondelis® (Trabectedin)

11/03/2009

Taiho Pharmaceutical and Toray Industries Now Working Together to Develop a ß3-Adrenoceptor Agonist

01/10/2008

Basic agreement reached with Nippon Shinyaku for the collaborative development and marketing of a new antipruritic agent (code NS-141)

01/10/2008

Domestic manufacture of downsized Uzel (calcium folinate) 25 mg tablets to be started soon

01/10/2008

Autumn 2008 version TV commercial for Tiovita Drink is aired

30/09/2008

Zosyn, a new injectable combination antibiotic of beta-lactamase inhibitor and penicillin domestically launched on October 1

30/09/2008

Taiho Pharmaceutical collaborates with and supports the Japan Pink Ribbon Campaign for this year

29/09/2008

46th fiscal-year (07/2007- 06/2008) report is released

22/09/2008

New website contents to promote medical check-ups for breast cancer are released

02/09/2008

The antipsoriatic ethical drugs, Urepearl-Plus Lotion 10 and Urepearl-Plus Cream are launched on September 3

20/08/2008

8th Oncology Media Seminar is held: Main topic - Current therapyfor breast cancer

25/07/2008

Notice: Three Otsuka group companies (Otsuka Pharmaceutical Factory, Otsuka Warehouse, and Taiho Pharmaceutical) are reorganized as wholly-owned direct subsidiaries

18/07/2008

License agreement with Sanofi-Aventis on TS-1 is terminated

18/07/2008

Results of a randomized comparative phase 3 study of S-1 in advanced/recurrent gastric cancer become available

16/07/2008

Notice: Acquisition of production/distribution license for Zosyn, a new injectable combination antibiotic of beta-lactamase inhibitor and penicillin

24/06/2008

Summer 2008 version TV commercial for Tiovita Drink is aired

07/04/2008

7th Oncology Media Seminar is opened: Main topic - Gastric cancer: Clinical studies of oral anti-gastric cancer agents and guidelines for the treatment of gastric cancer

25/03/2008

Results of a randomized comparative study of S-1 monotherapy compared to S-1 with cisplatin (SPIRITS trial) in advanced/recurrent gastric cancer is published in Lancet Oncology: New standard therapy for advanced gastric cancer anticipated

18/01/2008

Spring 2008 version TV commercial for Tiovita Drink is aired